Table 4.

Clinical characteristics of patients and DFS and CSS in univariate analysis

	N (%)	5-yr DFS %	P value″	5-yr CSS %	P value″
Molecular subclasses at diagnosis
HER2+, ER+ and/or PgR+°	125 (61.0)	78.4	0.06	89.2	0.04
HER2+, ER−, PgR− *	80 (39.0)	66.0	0.05	73.1	0.06
pCR/0 (ypT0, ypN0)
Yes	51 (24.8)	86.3	0.11	83.5	0.71
No	154 (75.2)	68.7	0.18	82.9	0.55
pCR/is (ypT0/is, ypN0)
Yes	96 (46.8)	82.3	0.12	86.3	0.18
No	109 (53.2)	65.7	0.12	79.7	0.10
Type of surgery
Breast conservative surgery	97 (47.3)	77.9	0.08	86.0	0.03
Mastectomy	108 (52.7)	67.9	0.05	76.9	0.01
Radiotherapy
Yes	142 (69.3)	79.5	0.96	83.6	0.32
No	63 (30.8)	72.0	0.73	83.0	0.26
Mastectomy
With radiotherapy	45 (41.7)	52.9	0.29	77.5	0.68
Without radiotherapy	63 (58.3)	77.4	0.48	78.7	0.66
Residual tumor size
ypT0/is	104 (50.7)	79.1	0.04	84.7	0.02
ypT1	55 (26.9)	75.8	0.03	86.6	0.006
ypT2	37 (18.0)	61.2		63.5
ypT3	9 (4.4)	55.6		65.6
Node involvement
ypN0	152 (74.1)	78.0	0.02	86.5	0.05
ypN+	53 (25.9)	58.9	0.02	66.7	0.05
Pathological stage
0^	96 (46.8)	82.3	0.005	83.5	0.02
I	35 (17.1)	84.4	0.006	100.0	0.02
II	67 (31.7)	54.5		64.3
III	7 (3.4)	71.4		75.0
Adjuvant chemotherapy
Nil	191(93.2)	76.4	0.63	81.3	0.64
Yes	14 (6.8)	43.6	0.85	85.7	0.54
Adjuvant Trastuzumab
Nil	10 (4.9)	56.2	0.64	87.5	0.91
Up to 52 weeks of treatment	195 (95.1)	74.7	0.64	70.9	0.81
Adjuvant hormonal therapy
Nil	91 (44.4)	68.1	0.14	75.0	0.12
Yes	114 (55.6)	77.8	0.09	86.9	0.14

HER2 Human epidermal growth factor type 2, ER estrogen receptors, PgR progesteron receptors

° Luminal B/HER2+, * nonluminal/HER2+, ^ ypT0/is, ypN0, ″ the first P value is determined by log-rank test and the second one by Tarone-Ware test